2025 Q3 -tulosraportti
14 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sittenHow should this news be understood ? https://news.cision.com/curasight/r/notice-of-extraordinary-general-meeting,c4281603·10 t sittenThe news you are linking to is an official notice for an extraordinary general meeting (EGM) of Curasight A/S, to be held on December 29, 2025, at 10:00 AM in Copenhagen. What is it about? Curasight (a Danish biotech company developing theranostic technology for cancer diagnostics and treatment with uTRACE® and uTREAT®) needs additional financing. On December 12, 2025, they completed a directed issue, where they issued approx. 2 million new shares and raised 16.4 million DKK before costs from institutional and professional investors. At the same time, they entered into an agreement for a convertible loan with Fenja Capital II A/S (a lender that often helps biotech companies with financing). This loan can be converted into shares in the future, giving the lender the opportunity to become a shareholder. The problem is that the board of directors does not have the necessary authorization to issue such convertible loans without pre-emptive rights for existing shareholders. Therefore, this extraordinary general meeting is now being convened to obtain the shareholders' approval. Main proposal on the agenda The board proposes to add a new article (5.3) to the articles of association, which gives them authorization to issue convertible loans until December 29, 2030. Maximum capital increase via conversion: Up to nominally DKK 125,313.30 (corresponding to approx. 2.5 million new shares of DKK 0.05 each). This occurs without pre-emptive rights for existing shareholders, and the conversion price may be below market price. If the loan is converted, it will dilute existing shareholders' ownership stake. How should this be understood? Positive: It is part of a larger financing package that strengthens Curasight's liquidity. The company is in a clinical development phase (e.g., Phase I trial with uTREAT® in brain cancer), and biotech companies often need ongoing capital to finance studies. This structure (issue + convertible loan) is common in the industry and provides flexibility without having to go to the market every time. Negative/risk: Without pre-emptive rights, it means potential dilution for current shareholders if the loan is converted into shares (especially if at a low price). It is typical for such loans that the lender receives favorable terms as compensation for the risk. Context: Curasight has had several capital raises in 2025 (e.g., directed issues and warrants earlier in the year). This indicates that the company is working to extend its "cash runway" to reach clinical milestones. If you are a shareholder, you can participate, vote by mail, or give proxy (deadline December 26). The proposal requires a simple majority to be adopted. In short: The news is a formality to complete a financing agreement that helps the company obtain more capital, but it may mean dilution for shareholders in the long term. This is standard in the biotech world, where cash burn is high.
·18 t sitten · MuokattuIt is good and right that the company raises capital and strengthens operations. I myself have written about this below, that Curasight should do it. But one can question why the company is doing it now instead of waiting for the next announcement? Everyone here expects quick positive news, and if the share price had then gone to 12-15, the emission could have been set at a higher price than 7.98? My assessment: positive and right with an emission and capital injection, but wrong timing, opinions?
·7 t sittenYou have to see it in a larger perspective. Curasight is not chasing a price of 12-15 in the coming weeks. That is not an independent goal. Why would it be? And honestly, people need to relax. Things are rising sharply and yet people want more. My take has always been that it would fluctuate between 4.5-5.5 throughout the autumn. The next jump would be to the 8-12 range where many factors play a role, including cash reserves. The only things that can change the price being these 8-10 for the next many weeks are: - preliminary data after FPD is surprisingly good (currently relatively good data is already priced into the stock) - curium money - acquisition talk (rumors are almost enough) Anything else, you should not expect to move the price other than back towards 8 sooner or later.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
14 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenHow should this news be understood ? https://news.cision.com/curasight/r/notice-of-extraordinary-general-meeting,c4281603·10 t sittenThe news you are linking to is an official notice for an extraordinary general meeting (EGM) of Curasight A/S, to be held on December 29, 2025, at 10:00 AM in Copenhagen. What is it about? Curasight (a Danish biotech company developing theranostic technology for cancer diagnostics and treatment with uTRACE® and uTREAT®) needs additional financing. On December 12, 2025, they completed a directed issue, where they issued approx. 2 million new shares and raised 16.4 million DKK before costs from institutional and professional investors. At the same time, they entered into an agreement for a convertible loan with Fenja Capital II A/S (a lender that often helps biotech companies with financing). This loan can be converted into shares in the future, giving the lender the opportunity to become a shareholder. The problem is that the board of directors does not have the necessary authorization to issue such convertible loans without pre-emptive rights for existing shareholders. Therefore, this extraordinary general meeting is now being convened to obtain the shareholders' approval. Main proposal on the agenda The board proposes to add a new article (5.3) to the articles of association, which gives them authorization to issue convertible loans until December 29, 2030. Maximum capital increase via conversion: Up to nominally DKK 125,313.30 (corresponding to approx. 2.5 million new shares of DKK 0.05 each). This occurs without pre-emptive rights for existing shareholders, and the conversion price may be below market price. If the loan is converted, it will dilute existing shareholders' ownership stake. How should this be understood? Positive: It is part of a larger financing package that strengthens Curasight's liquidity. The company is in a clinical development phase (e.g., Phase I trial with uTREAT® in brain cancer), and biotech companies often need ongoing capital to finance studies. This structure (issue + convertible loan) is common in the industry and provides flexibility without having to go to the market every time. Negative/risk: Without pre-emptive rights, it means potential dilution for current shareholders if the loan is converted into shares (especially if at a low price). It is typical for such loans that the lender receives favorable terms as compensation for the risk. Context: Curasight has had several capital raises in 2025 (e.g., directed issues and warrants earlier in the year). This indicates that the company is working to extend its "cash runway" to reach clinical milestones. If you are a shareholder, you can participate, vote by mail, or give proxy (deadline December 26). The proposal requires a simple majority to be adopted. In short: The news is a formality to complete a financing agreement that helps the company obtain more capital, but it may mean dilution for shareholders in the long term. This is standard in the biotech world, where cash burn is high.
- ·18 t sitten · MuokattuIt is good and right that the company raises capital and strengthens operations. I myself have written about this below, that Curasight should do it. But one can question why the company is doing it now instead of waiting for the next announcement? Everyone here expects quick positive news, and if the share price had then gone to 12-15, the emission could have been set at a higher price than 7.98? My assessment: positive and right with an emission and capital injection, but wrong timing, opinions?·7 t sittenYou have to see it in a larger perspective. Curasight is not chasing a price of 12-15 in the coming weeks. That is not an independent goal. Why would it be? And honestly, people need to relax. Things are rising sharply and yet people want more. My take has always been that it would fluctuate between 4.5-5.5 throughout the autumn. The next jump would be to the 8-12 range where many factors play a role, including cash reserves. The only things that can change the price being these 8-10 for the next many weeks are: - preliminary data after FPD is surprisingly good (currently relatively good data is already priced into the stock) - curium money - acquisition talk (rumors are almost enough) Anything else, you should not expect to move the price other than back towards 8 sooner or later.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
14 päivää sitten36 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenHow should this news be understood ? https://news.cision.com/curasight/r/notice-of-extraordinary-general-meeting,c4281603·10 t sittenThe news you are linking to is an official notice for an extraordinary general meeting (EGM) of Curasight A/S, to be held on December 29, 2025, at 10:00 AM in Copenhagen. What is it about? Curasight (a Danish biotech company developing theranostic technology for cancer diagnostics and treatment with uTRACE® and uTREAT®) needs additional financing. On December 12, 2025, they completed a directed issue, where they issued approx. 2 million new shares and raised 16.4 million DKK before costs from institutional and professional investors. At the same time, they entered into an agreement for a convertible loan with Fenja Capital II A/S (a lender that often helps biotech companies with financing). This loan can be converted into shares in the future, giving the lender the opportunity to become a shareholder. The problem is that the board of directors does not have the necessary authorization to issue such convertible loans without pre-emptive rights for existing shareholders. Therefore, this extraordinary general meeting is now being convened to obtain the shareholders' approval. Main proposal on the agenda The board proposes to add a new article (5.3) to the articles of association, which gives them authorization to issue convertible loans until December 29, 2030. Maximum capital increase via conversion: Up to nominally DKK 125,313.30 (corresponding to approx. 2.5 million new shares of DKK 0.05 each). This occurs without pre-emptive rights for existing shareholders, and the conversion price may be below market price. If the loan is converted, it will dilute existing shareholders' ownership stake. How should this be understood? Positive: It is part of a larger financing package that strengthens Curasight's liquidity. The company is in a clinical development phase (e.g., Phase I trial with uTREAT® in brain cancer), and biotech companies often need ongoing capital to finance studies. This structure (issue + convertible loan) is common in the industry and provides flexibility without having to go to the market every time. Negative/risk: Without pre-emptive rights, it means potential dilution for current shareholders if the loan is converted into shares (especially if at a low price). It is typical for such loans that the lender receives favorable terms as compensation for the risk. Context: Curasight has had several capital raises in 2025 (e.g., directed issues and warrants earlier in the year). This indicates that the company is working to extend its "cash runway" to reach clinical milestones. If you are a shareholder, you can participate, vote by mail, or give proxy (deadline December 26). The proposal requires a simple majority to be adopted. In short: The news is a formality to complete a financing agreement that helps the company obtain more capital, but it may mean dilution for shareholders in the long term. This is standard in the biotech world, where cash burn is high.
- ·18 t sitten · MuokattuIt is good and right that the company raises capital and strengthens operations. I myself have written about this below, that Curasight should do it. But one can question why the company is doing it now instead of waiting for the next announcement? Everyone here expects quick positive news, and if the share price had then gone to 12-15, the emission could have been set at a higher price than 7.98? My assessment: positive and right with an emission and capital injection, but wrong timing, opinions?·7 t sittenYou have to see it in a larger perspective. Curasight is not chasing a price of 12-15 in the coming weeks. That is not an independent goal. Why would it be? And honestly, people need to relax. Things are rising sharply and yet people want more. My take has always been that it would fluctuate between 4.5-5.5 throughout the autumn. The next jump would be to the 8-12 range where many factors play a role, including cash reserves. The only things that can change the price being these 8-10 for the next many weeks are: - preliminary data after FPD is surprisingly good (currently relatively good data is already priced into the stock) - curium money - acquisition talk (rumors are almost enough) Anything else, you should not expect to move the price other than back towards 8 sooner or later.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt